Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Atezolizumab + Carboplatin + Paclitaxel|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Atezolizumab||Tecentriq||RG7446|MPDL3280A||Immune Checkpoint Inhibitor 147 PD-L1/PD-1 antibody 87||Tecentriq (atezolizumab) is a monoclonal antibody against PD-L1 (CD274), preventing activation of its receptor, potentially enhancing T-cell-mediated immune response to neoplasms and inhibiting T-cell inactivation (PMID: 29449897). Tecentriq (atezolizumab) is FDA approved for use in PD-L1 positive advanced or metastatic urothelial carcinoma not eligible for cisplatin-containing chemotherapy, in advanced or metastatic urothelial carcinoma not eligible for chemotherapy or progressed on platinum-based chemotherapy, in metastatic non-small cell lung cancer (NSCLC) progressed on platinum-containing therapy, as first-line therapy in metastatic NSCLC with high PD-L1 expression (TC>=50% or IC>=10%) and without EGFR or ALK alterations, for adjuvant treatment in patients with PD-L1-positive (>=1% tumor cell expression) NSCLC, in combination with bevacizumab, paclitaxel, and carboplatin as first-line therapy for non-squamous NSCLC with no EGFR or ALK aberrations, in combination with paclitaxel protein-bound and carboplatin in metastatic non-squamous NSCLC with no EGFR or ALK aberrations, in combination with paclitaxel protein-bound in advanced or metastatic triple-negative breast cancer expressing PD-L1, in combination with carboplatin and etoposide in extensive-stage small cell lung cancer, in combination with bevacizumab in hepatocellular carcinoma without prior systemic therapy, and in combination with cobimetinib and vemurafenib in BRAF V600-mutated melanoma (FDA.gov).|
|Carboplatin||Paraplatin||CBDCA||Chemotherapy - Platinum 7||Paraplatin (carboplatin) is a second-generation platinum compound and is activated intracellularly to form reactive platinum complexes that cross link DNA with DNA and with proteins. This induces apoptosis and inhibits cell growth (NCI Drug Dictionary).|
|Paclitaxel||Taxol||7-Epipaclitaxel||Antimicrotubule Agent 13 BCL2 Family Inhibitor 6||Taxol (paclitaxel) binds to tubulin to inhibit microtubule disassembly, which results in decreased cell division, and also binds to the anti-apoptotic factor Bcl-2, promoting apoptosis (NCI Drug Dictionary).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT03598270||Phase III||Carboplatin + Gemcitabine Niraparib Carboplatin + Pegylated liposomal-doxorubicin Atezolizumab + Carboplatin + Pegylated liposomal-doxorubicin Atezolizumab + Carboplatin + Gemcitabine Atezolizumab + Carboplatin + Paclitaxel Carboplatin + Paclitaxel Atezolizumab + Niraparib||Platinum-based Chemotherapy With Atezolizumab and Niraparib in Patients With Recurrent Ovarian Cancer (ANITA)||Active, not recruiting||ITA | FRA | ESP | DEU | BEL||0|
|NCT03603184||Phase III||Atezolizumab + Carboplatin + Paclitaxel Carboplatin + Paclitaxel||Atezolizumab Trial in Endometrial Cancer - AtTEnd (AtTEnd)||Active, not recruiting||ITA | ESP | DEU | AUT||7|
|NCT03977194||Phase III||Atezolizumab + Carboplatin + Paclitaxel Carboplatin + Paclitaxel||Atezolizumab in Elderly Patients With Advanced Non-Small-Cell Lung Cancer and Receiving Carboplatin Paclitaxel Chemotherapy (ELDERLY)||Recruiting||FRA||0|
|NCT04776447||Phase II||Atezolizumab + Carboplatin + Paclitaxel||Atezolizumab Plus Induction Chemotherapy Plus CT-radiotherapy. (APOLO)||Recruiting||ESP||0|
|NCT03394885||Phase Ib/II||Atezolizumab + Carboplatin + Paclitaxel||Atezolizumab With Neoadjuvant Chemotherapy for Patients With Newly-Diagnosed Advanced-Stage Ovarian Cancer (AdORN)||Completed||USA||0|
|NCT04770272||Phase II||Atezolizumab + Carboplatin + Paclitaxel Atezolizumab + Cyclophosphamide + Epirubicin Atezolizumab||Study to Compare a Mono Atezolizumab Window Followed by a Atezolizumab - CTX Therapy With Atezolizumab - CTX Therapy (neoMono)||Recruiting||DEU||0|
|NCT01633970||Phase I||Atezolizumab + Carboplatin + Paclitaxel Atezolizumab + Carboplatin + Pemetrexed Disodium Atezolizumab + Bevacizumab + Capecitabine||A Phase 1b Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) in Combination With Avastin (Bevacizumab) and/or With Chemotherapy in Patients With Locally Advanced or Metastatic Solid Tumors||Completed||USA||0|
|NCT02883062||Phase II||Carboplatin + Paclitaxel Atezolizumab + Carboplatin + Paclitaxel||Carboplatin and Paclitaxel With or Without Atezolizumab Before Surgery in Treating Patients With Newly Diagnosed, Stage II-III Triple-Negative Breast Cancer||Active, not recruiting||USA||0|
|NCT02366143||Phase III||Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel Bevacizumab + Carboplatin + Nab-paclitaxel Atezolizumab + Carboplatin + Paclitaxel||TBAA Phase III Study of MPDL3280A (Anti-PD-L1 Antibody) in Combination With Carboplatin + Paclitaxel With or Without Bevacizumab in Patients With Stage IV Non-squamous Non-small Cell Lung Cancer||Completed||USA | ITA | FRA | ESP | DEU | CAN | BEL | AUT||18|